These revealed 27 germline BRCA2 variants (6%), but only two germline BRCA1 variants (0.5%), and one of these probably wasn't the driver as an ATM mutation was also present, note the researchers.

These revealed 27 germline BRCA2 variants (6%), but only 2 germline BRCA1 variants (0.5%), and one of these probably wasn't the driver as an ATM mutation was also present, note the researchers.

Thus, mutations in BRCA1 and BRCA2 should not be lumped together ... the investigators reviewed results of germline and somatic DNA testing from 450 patients with localized or metastatic prostate ...

Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami ...

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

The presence of biomarkers, even in small amounts, can shape the course of treatment for a patient, says Andy Guinigundo, MSN, RN, CNP, ANP-BC.

All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with other drugs are being investigated. Clinical PARP inhibitors: where are we now?

[38,39] Risk-reducing strategies have been shown to have associations with a gain in life expectancy in BRCA1/2 carriers. Moreover, extended life expectancy can range from between a few months to ...